According to filings with the U.S. Securities and Exchange Commission, Immunome is raising $230,000,000.00 in new funding. About Immunome: Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and antibody drug conjugates (ADCs). We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. Our work is also supported by the Immunome Discovery Engine, which identifies potentially novel targets and antibodies. Patient immune systems recognize disease-related antigens, leading to the formation of memory B cells. Our platform isolates B cells from patient samples, expands them, and then uses proprietary hybridoma technology to immortalize them. The highly optimized system can screen up to 20,000 antibodies at a time, incorporating both functional and sequence-based elements. The selected antibodies and targets are then evaluated for therapeutic potential, whether as ADCs or as naked antibodies.

To learn more about Immunome, visit http://immunome.com/

Contact:
Clay Siegall, President and Chief Executive Officer
610-321-3700

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.